Peer-reviewed veterinary case report
Radiation and liposomal doxorubicin for advanced cat soft tissue
By Kleiter, Miriam et al.·Published in Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2010·University of Veterinary Medicine Vienna·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Concomitant liposomal doxorubicin and daily palliative radiotherapy in advanced feline soft tissue sarcomas.
- Species:
- cat
Plain-English summary
Ten cats with advanced soft tissue sarcomas were treated with a combination of liposomal doxorubicin and daily radiation therapy to see if it could help control their tumors. Most of the cats responded well, with seven out of ten showing either partial or complete improvement, lasting an average of about 237 days. The treatment was generally well-tolerated, with only one cat experiencing temporary loss of appetite. While more research is needed, these results suggest that this combination therapy could be a promising option for managing this type of cancer in cats.
People also search for: cat soft tissue sarcoma treatment · feline cancer radiation therapy · liposomal doxorubicin for cats
Abstract
Local recurrence of feline soft tissue sarcomas is common despite aggressive treatment. Liposomal doxorubicin might serve as a depot radiosensitizer if administered concomitantly with daily radiotherapy and thus improve tumor control. In this pilot study, the feasibility of concomitant liposomal radiochemotherapy was evaluated in a palliative setting in 10 cats with advanced soft tissue sarcomas. Cats were treated with median number of 5 (range 5-7) daily fractions of radiotherapy and a median total dose of 20 Gy (range 20-31.5 Gy). One dose of liposomal doxorubicin was administered at the beginning of radiotherapy. Seven cats received further free or liposomal doxorubicin after completion of the liposomal doxorubicin/radiation protocol. Seven of the treated 10 cats (70%) achieved a partial (n=5) or complete (n=2) response with a median response duration of 237 days. The median progression free interval in all 10 cats was 117 days and the median overall survival time was 324 days. Concomitant liposomal radiochemotherapy was tolerated well in nine cats, one cat experienced temporary anorexia. Although the number of patients is too small to make definitive conclusions, results appear promising enough to investigate the role of liposomal doxorubicin as a radiosensitizer further.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20469561/